Blood cancer patients undergoing chemotherapy could soon have a reduced dependence on blood transfusions thanks to a new clinical study announced, run in partnership between biotech company Syntara (ASX: SNT), the University of Newcastle and the Australasian Leukaemia and Lymphoma Group (ALLG). The Phase 2 clinical study has been backed by a $0.83m grant to
Read More
Heads have turned in biotech circles with an ASX filing confirming that Platinum Asset Management has increased its stake in clinical-stage drug developer Syntara to 19.24%, fresh off the commencement of a Phase 2a clinical study that has the potential to become a new treatment for patients diagnosed with myelofibrosis (bone marrow cancer). The combination
Read More
Clinical stage drug development company Syntara (ASX:SNT) is set to get a big boost in exposure within the blood cancer industry as it forges ahead with dosing patients in its Phase 2 clinical trial of SNT-5505 in combination with approved drug ruxolitinib. SNT-5505, a pan-LOX inhibitor designed to target myelofibrosis, a bone marrow cancer where
Read More
With a burgeoning pipeline of drugs deeply advanced, clinical stage biopharmaceuticals company Pharmaxis (ASX: PXS) has streamlined its business with the sale of its mannitol respiratory business (MBU) and will now will focus their resources towards a much larger commercial opportunity in blood cancers haematological malignancies, aka blood cancers. The definitive sale agreement of its
Read More
Each year, more than 4,000 Australians are diagnosed with pancreatic cancer, a form of cancer which is difficult to diagnose and with limited treatment options. Thanks to a new study conducted by the Garvan Institute of Medical Research, however, a drug developed by biotech company Pharmaxis (ASX: PXS) could increase patient survival rates by 35%.
Read More
In a potential breakthrough for the field of bone marrow cancer treatment, biotech company Pharmaxis (ASX: PXS) has released the final interim data analysis of their Phase 2 clinical trials for PXS-5505, a promising drug aimed at combating the debilitating effects of myelofibrosis. The data revealed 60% of trial patients experienced a significant improvement in
Read More